Theralase Technologies Inc

F:TTX

Clinical progress: Theralase completed enrollment in its Phase II bladder cancer study with 92 patients, including 82 who have completed the study and 10 still under assessment.

Regulatory timeline: Management plans to submit a rolling new drug application to Health Canada and the FDA in the third quarter of 2026, with marketing decisions expected in the first half of 2027.

Study results: Ruvidar produced a 65% complete response rate and a 73% total response rate at any point in the study; 40% of complete responders maintained the response at 15 months or longer.

Financial performance: First-quarter revenue increased 45% year over year to $133,000, while the net loss declined 30% to $1.032 million.

Capital position: The company raised approximately $7.5 million year to date and closed a further $4.8 million offering on May 20; it is also exploring a U.S. IPO for late 2026 or early 2027.

Pipeline expansion: Theralase is advancing Rutherrin and other programs across brain, lung, pancreatic, colorectal, hematologic and muscle-invasive bladder cancers, as well as topical Ruvidar for cold sores.

Near-term catalysts: Planned milestones include GLP toxicology completion, adaptive clinical studies for new indications, a potential Ruvidar-ADSTILADRIN combination study with Ferring, and possible U.S. listing activities.